Histone Acetyltransferase
HATs; HAT
Histone acetyltransferases (HATs) are epigenetic enzymes that install acetyl groups onto lysine residues of cellular proteins such as histones, transcription factors, nuclear receptors, and enzymes. HATs are crucial for chromatin restructuring and transcriptional regulation in eukaryotic cells. HATs have been shown to play a role in diseases ranging from cancer and inflammatory diseases to neurological disorders, both through acetylations of histone proteins and non-histone proteins.
HATs can be grouped into at least five different subfamilies (HAT1, Gcn5/PCAF, MYST, p300/CBP, and Rtt109). HATs mediate many different biological processes including cell-cycle progression, dosage compensation, repair of DNA damage, and hormone signaling. Aberrant HAT function is correlated with several human diseases including solid tumors, leukemias, inflammatory lung disease, viral infection, diabetes, fungal infection, and drug addiction.
Histone Acetyltransferase Isoform Specific Products
All Product Categories
-
Histone Acetyltransferase Inhibitors
(182)
View all products
-
Histone Acetyltransferase Agonist
(1)
View all products
-
Histone Acetyltransferase Activators
(12)
View all products
-
Histone Acetyltransferase Modulators
(3)
View all products
-
Histone Acetyltransferase Degraders
(39)
View all products
-
Histone Acetyltransferase Controls
(5)
View all products
-
Histone Acetyltransferase Substrates
(5)
View all products
-
Histone Acetyltransferase Ligands
(11)
View all products
-
Histone Acetyltransferase Related Products (285)
Related Products (285)
-
Antibodies (25)
-
Histone Acetyltransferase Isoform Comparison
-
PROTAC CBP/P300 Degrader-4
0 ImagesCat. No.: HY-183802PROTAC CBP/P300 Degrader-4 is a p300/CBP PROTAC degrader with DC50 of 17.4 nM and 10.2 nM against p300 and CBP in U2OS cells, respectively. PROTAC CBP/P300 Degrader-4 forms ternary complexes with p300 or CBP and an E3 ligase, drives ubiquitination, and mediates proteasomal degradation. PROTAC CBP/P300 Degrader-4 can be used for the research of hematological malignancies.
-
Procyanidin B3 (Standard)
0 ImagesCat. No.: HY-N2345RCAS No.: 23567-23-9Procyanidin B3 (Standard) is the analytical standard of Procyanidin B3. This product is intended for research and analytical applications. Procyanidin B3 is a natural product with antioxidant activity and oral bioavailability, possessing good blood-brain barrier penetration. Procyanidin B3 is a selective inhibitor of histone acetyltransferase (HAT). By inhibiting p300 HAT-mediated acetylation of the androgen receptor (androgen receptor). Procyanidin B3 alleviates intervertebral disc degeneration (IVDD) by inhibiting the formation of the TLR4/MD-2 complex. Procyanidin B3 can be used in research on prostate cancer and arthritis.
-
Y08262
0 ImagesCat. No.: HY-157134CAS No.: 2450965-18-9Y08262 is a potent and selective CBP bromodomain inhibitor. Y08262 selectively inhibits the CBP bromodomain with an IC50 value of 73.1 nM. Y08262 can be used for the research of acute myeloid leukemia (AML).
-
HDAC-IN-99
0 ImagesCat. No.: HY-181843HDAC-IN-99 is a histone deacetylase (HDAC) inhibitor with an IC50 of 37.73 nM, and it exhibits potent inhibitory activity against HDAC1 (IC50 = 48.09 nM), HDAC2 (IC50 = 300.28 nM) and HDAC6 (IC50 = 9.16 nM). HDAC-IN-99 exerts broad-spectrum antiproliferative activity in various cancer cell lines. HDAC-IN-99 induces S-phase cell cycle arrest and apoptosis in colon cancer cells, increases the acetylation levels of histone H3, histone H4 and α-tubulin, and upregulates the expression of p21 as well as the cleavage of caspase-3. HDAC-IN-99 displays antitumor activity in colon cancer xenograft models. HDAC-IN-99 can be used for the research of colon cancer.
-
KCN1
0 ImagesCat. No.: HY-123009CAS No.: 927823-01-6KCN1 is a p300/HIF-1α interaction inhibitor with a Kd value of 345 nM for p300-CH1. KCN1 binds to the CH1 domain of p300, blocks the assembly of the p300/HIF-1α complex, and disrupts the HIF-1α-p300/CBP interaction. KCN1 inhibits cancer cell growth, induces cancer cell cycle arrest and apoptosis. KCN1 inhibits β-galactosidase activity and downregulates the expression of VEGF, Glut1, CA9 and CAIX. KCN1 exerts anticancer activity in mouse tumor xenograft models. KCN1 can be used in research related to malignant glioma, pancreatic cancer and metastatic uveal melanoma.
-
KP 544
0 ImagesCat. No.: HY-11055CAS No.: 393856-87-6KP 544 is a potent neurotrophic protein enhancer that amplifies nerve growth factor (NGF)-induced neurite outgrowth of PC12 cells and SH-SY5Y neuroblastoma cells. KP544 also enhances choline acetyltransferase activity. KP 544 selectively interact in the differentiation pathway downstream of MAPK in a manner that amplifies nerve growth factor and cyclic AMP effects and is also neuroprotective.
-
EP300/CBP ligand 2
0 ImagesCat. No.: HY-161960EP300/CBP ligand 2 (compound S19) is a ligand targeting the bromodomain of CREB binding protein (CBP) and E1A-associated protein (EP300). EP300/CBP ligand 2 can be used as a target protein ligand in the PROTAC structure, and can be coupled to the E3 ubiquitin ligase ligand through the PTOTAC Linker to synthesize PROTAC molecules with degradation effects. For example, EP300/CBP ligand 2 can be coupled with the conjugate (E3 ubiquitin enzyme ligand + Linker) Thalidomide-NH-C10-Boc (HY-161961) to produce the PROTAC molecule dCE-2 (HY-161958).
-
NP1192
0 ImagesNP1192 is a potent, selective PROTAC NAT10 degrader. NP1192 promotes NAT10 ubiquitination and degradation. NP1192 inhibits ac4C modification. NP1192 demonstrates dual inhibition of hypoxia-driven glycolysis and immunosuppression via NAT10/HIF-1α/PD-L1 axis disruption, achieving superior antitumor efficacy and synergizing with anti-PD-L1 both in vitro and in vivo. NP1192 can be used for ovarian, cervical, and glioblastoma cancer research.
-
PCAF/GCN5 ligand 1
0 ImagesCat. No.: HY-181279CAS No.: 1209224-91-8PCAF/GCN5 ligand 1 is a PCAF/GCN5 ligand with high binding affinity. PCAF/GCN5 ligand 1 shows no functional effect on PCAF/GCN5 activity. PCAF/GCN5 ligand 1 undergoes optimization into a potent and selective PCAF/GCN5 ligand GSK4027 (HY-101027).
-
Antitumor agent-130
0 ImagesCat. No.: HY-162128CAS No.: 3048422-07-4Antitumor agent-130 (Compound 7b) is a p300 histone acetyltransferases (HAT) inhibitor with an IC50 of 1.51 μM. Antitumor agent-130 combinates with doxorubicin (HY-15142A) can significantly inhibit tumor growth and invasion in vitro and in vivo.
-
KAT6A-IN-1
0 ImagesCat. No.: HY-162994CAS No.: 2991087-72-8KAT6A-IN-1 is a KAT6A inhibitor with an IC50 of <10 μM. KAT6A-IN-1 can be used for the research of cancer.
-
CBP/p300 ligand 5
0 ImagesCat. No.: HY-161711CBP/p300 ligand 5 is the target protein ligand of XYD129 (HY-161710). CBP/p300 ligand 5 can be used to study the acute myelogenous leukemia.
-
Y16524
0 ImagesCat. No.: HY-168463CAS No.: 3109988-90-8Y16524 is a potent inhibitor of CBP/p300 bromodomain , with the IC50 of 0.01 μM. Y16524 has the potential for the research of acute myeloid leukemia (AML).
-
CBP/p300/BRD4 ligand-1
0 ImagesCat. No.: HY-181759CAS No.: 3086024-48-5CBP/p300/BRD4 ligand-1 is a small-molecule inhibitor targeting CBP, p300, and BRD4. CBP/p300/BRD4 ligand-1 competitively binds to the functional domains of target proteins without disrupting key interactions. CBP/p300/BRD4 ligand-1 can be used for the construction of dual-target PROTAC degraders (HY-181758) in studies related to prostate cancer and other cancers.
-
ACTR-AD1 2L
0 ImagesCat. No.: HY-P11829ACTR-AD1 2L is a ACTR-AD1 peptide. ACTR-AD1 2L inhibits CBP/p300-NCOA3 complex formation, modulates gene transcription, inhibits CBP/p300 acetylase activity, reduces acetylation levels, and exhibits antiproliferative activity. ACTR-AD1 2L binds with stronger affinity to its target proteins than the wild-type peptide. ACTR-AD1 2L can be used for the research of breast cancer.
-
Ep300/CREBBP-IN-2
0 ImagesCat. No.: HY-128363CAS No.: 2259641-59-1Ep300/CREBBP-IN-2 (Example 73) is a potent and orally active Ep300 and CREBBP inhibitor with IC50s of 0.052 and 0.148 μM, respectively. Ep300/CREBBP-IN-2 can be used for the research of cancer.
-
CoA-C2-SGRGK-cCPP
0 ImagesCat. No.: HY-P11824CoA-C2-SGRGK-cCPP is a NatD (NAA40) bisubstrate inhibitor with an IC50 of 78 nM and a Ki of 39 nM. CoA-C2-SGRGK-cCPP competitively targets the peptide substrate binding site and noncompetitively targets the CoA binding site of NatD to block acetyltransferase activity. CoA-C2-SGRGK-cCPP reduces cellular Nα-acetylation on histone H4, modulates EMT marker expression. CoA-C2-SGRGK-cCPP can be used for the research of non-small cell lung cancer.
-
CBP/p300-IN-17
0 ImagesCat. No.: HY-143441CAS No.: 2259640-87-2CBP/p300-IN-17 (compound 7) is a potent EP300/CBP HAT inhibitor with IC50s of 0.18, 0.69 µM for HAT EP300 and LK2 H3K27, respectively.
-
CBP/p300 ligand-Linker Conjugate 3
0 ImagesCat. No.: HY-186064CAS No.: 3102127-04-5
-
PROTAC KAT2A/B degrader-1
0 ImagesCat. No.: HY-181695CAS No.: 3031606-85-3PROTAC KAT2A/B degrader-1 is an orally active CRBN-baed histone acetyltransferase KAT2A/KAT2B PROTAC degrader. PROTAC KAT2A/B degrader-1 induces degradation of KAT2A and KAT2B proteins. PROTAC KAT2A/B degrader-1 inhibits proliferation of acute myeloid leukemia and small cell lung cancer cells. PROTAC KAT2A/B degrader-1 can be used for the research of acute myeloid leukemia, small cell lung cance.
